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Abstract  Invasive  mechanical  ventilation  (IMV)  represents  a  risk  factor  for  the  development  of
ventilator-associated  pneumonia  (VAP),  which  develops  at  least  48  h  after  admission  in  patients
ventilated through  tracheostomy  or  endotracheal  intubation.  VAP  is  the  most  frequent  intensive-
care-unit (ICU)-acquired  infection  among  patients  receiving  IMV.  It  contributes  to  an  increase
in hospital  mortality,  duration  of  MV  and  ICU  and  length  of  hospital  stay.  Therefore,  it  wors-
ens the  condition  of  the  critical  patient  and  increases  the  total  cost  of  hospitalization.  The
introduction  of  preventive  measures  has  become  imperative,  to  ensure  control  and  to  reduce
the incidence  of  VAP.  Preventive  measures  focus  on  modifiable  risk  factors,  mediated  by  non-
pharmacological  and  pharmacological  evidence  based  strategies  recommended  by  guidelines.
These measures  are  intended  to  reduce  the  risk  associated  with  endotracheal  intubation  and
to prevent  microaspiration  of  pathogens  to  the  lower  airways.
© 2013  Sociedade  Portuguesa  de  Pneumologia.  Published  by  Elsevier  España,  S.L.  All  rights
reserved.
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Prevenc¸ão  de  pneumonia  associada  ao  uso  do  ventilador
Resumo  A  ventilac¸ão  mecânica  invasiva  representa  um  fator  de  risco  para  o  desenvolvimento
da pneumonia  associada  ao  ventilador  (PAV),  que  se  desenvolve  48  horas  ou  mais  após  a  admis-
são hospitalar,  em  doentes  ventilados  através  de  traqueostomia  ou  intubac¸ão  endotraqueal.
A PAV  é  a  infec¸ão  adquirida  na  unidade  de  cuidados  intensivos  (UCI)  mais  frequente  entre
os doentes  submetidos  a  ventilac¸ão  mecânica  invasiva.  Contribui  para  o  aumento  da  mortal-
idade hospitalar,  da  durac¸ão  da  ventilac¸ão  mecânica  e  do  tempo  de  internamento  na  UCI  e
no hospital.  Por  conseguinte,  agrava  o  estado  de  saúde  do  doente  crítico  e  aumenta  o  custo
total da  hospitalizac¸ão.  A  adoc¸ão  de  medidas  preventivas  é  imprescindível,  de  modo  a  garan-
tir o  controlo  e  a  diminuic¸ão  da  incidência  da  PAV.  As  medidas  preventivas  incidem  sobre  os
fatores de  risco  modificáveis,  sendo  aplicadas  estratégias  não  farmacológicas  e  farmacológicas
baseadas na  evidência  e  recomendadas  por  guidelines.  As  medidas  preventivas  têm  como
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finalidade  diminuir  o  risco  associado  à  intubac¸ão  endotraqueal  e  prevenir  a  microaspirac¸ão  de
microrganismos  patogénicos  para  as  vias  aéreas  inferiores.
© 2013  Sociedade  Portuguesa  de  Pneumologia.  Publicado  por  Elsevier  España,  S.L.  Todos  os
direitos reservados.
Introduction
Invasive  mechanical  ventilation  is  a  risk  factor  for  the  devel-
opment  of  pneumonia,1,2 being  the  ventilator-associated
pneumonia  (VAP)  a  public  health  problem.  VAP  is  a  hospital-
acquired  pneumonia  which  occurs  in  patients  who  were
subjected  to  invasive  mechanical  ventilation,  whether
through  tracheostomy  or  endotracheal  intubation,  at  least
48  hours  before  the  onset  of  infection  and  that  were  ven-
tilated  at  the  onset  of  the  pneumonia.3 This  disease  is  also
classified  according  to  the  time  elapsed  from  the  beginning
of  the  mechanical  ventilation  (MV)  to  the  onset  of  pneumo-
nia;  it  is  considered  as  early-onset  if  it  occurs  within  4  days
of  the  start  of  MV,  and  late-onset  if  it  occurs  after  5  or  more
days  of  MV  onset.4,5 However,  not  all  the  studies  consider
early-  and  late-onset  VAP  within  the  same  time  range  frame
(Table  1).
VAP  occurs  primarily  in  intensive  care  units  (ICU),6 where
the  most  debilitated  patients  are  hospitalized,  often  requir-
ing  ventilatory  support.  It  is  estimated  that  from  8  to  28%
of  the  patients  receiving  MV  develop  pneumonia,  the  risk  is
between  3  and  10  times  higher  compared  to  patients  who
do  not  receive  MV.7 Furthermore,  almost  90%  of  episodes  of
nosocomial  pneumonia  registered  in  ICU  occur  during  MV.5
The  predisposing  risk  factors  for  the  development  of  the  dis-
ease  are  innumerable  and  are  divided  into  three  groups  as
schematized  in  Table  2:  related  with  the  host,  the  hospital-
ization  process  and  with  drug  therapy.
An  episode  of  VAP  may  be  due  to  a  single  pathogen  or  can
have  polymicrobial  origin.5,8,9 The  etiology  of  VAP  is  quite
diverse:  bacterial,  fungal  and  viral;  fungi  and  viruses  repre-
sent  a  greater  role  when  the  immune  system  of  the  patients
is  weakened.8,10 The  most  common  bacteria  are  listed  in
Table  3.
VAP  is  one  of  the  major  factors  contributing  to  morbid-
ity  and  mortality  in  the  ICU.11 A  meta-analysis  found  that
the  average  attributable  mortality  to  VAP  is  32.5%  in  the
ICU,12 supported  by  another  study13 that  found  33%.  VAP
increases  the  ICU  and  hospital  length  of  stay,  as  well  as
the  time  the  patient  requires  ventilatory  support.13,14 This
pathology  is  also  responsible  for  more  than  half  of  the  pre-
scribed  antibiotics  in  the  ICU5 and  for  the  increased  cost
of  hospital  internment,  registering  a  wide  range  of  values
for  the  average  cost  attributable  to  the  disease  (between
Table  1  Different  definitions  of  early  and  late-onset  VAP.
Citation  Early-onset  VAP  Late-onset  VAP
Park,  200510 ≤4--7  days  >7  days
Olaechea  et  al.,  201085 ≤7  days  >7  days
Erbay  et  al.,  200416 ≤3--5  days  >3--5  days
2089.13D  and  >29431.70D ).14--18 Due  to  all  this,  the  search
for  preventive  measures  in  order  to  reduce  these  param-
eters,  as  well  as  to  prevent  the  onset  of  the  disease,  has
become  imperative.19,20
Pathogenesis
There  are  several  sources  of  VAP  pathogens  that  can  be
classified  as  exogenous  and  endogenous  in  relation  to  the
patient  (Fig.  1).  The  exogenous  sources  are  mostly  from
aerosols  of  the  contaminated  air,  medical  devices  (humidi-
fier,  ventilatory  circuit,  catheter  and  bronchoscope),  health
professionals  and  other  patients.  The  endogenous  sources
are  represented  by  the  oral,  pharyngeal  and  gastric  flora  of
the  patient.21,22
Microorganisms  reach  the  lower  respiratory  tract  mainly
by  microaspiration  of  oropharyngeal  secretions  or  secret-
ions  that  are  aspirated  to  the  oropharynx  through  gastric
reflux;  and  secondarily  by  direct  extension  of  a  contigu-
ous  infection,  inhalation  of  contaminated  aerosols  or  by
hematogenous  spread  of  microorganisms  from  other  sites  of
infection.21,23
The  defense  mechanisms  against  lung  infection  in  a
healthy  non  smoker  include:  the  anatomy  of  airways,  cough
reflex,  mucus  production,  mucociliary  clearance,  lacto-
ferrin,  basement  membrane  and  the  immune  system.21,24
Not  all  defense  mechanisms  are  operational  in  critically
ill  patients  due  to  underlying  diseases,  sedative  medica-
tion,  poor  nutrition  and  medical  devices,22 such  as  the
endotracheal  tube  (ETT)  which  is  used  in  the  MV  and  com-
promises  the  cough  reflex  and  the  mucociliary  clearance
(ETT  increases  mucous  secretion  and  stagnation  of  secret-
ions)  and  causes  lesions  on  the  surface  of  the  tracheal
epithelium.21,25 The  ETT  cuff  prevents  the  aspiration  of  large
volume  secretions;  however,  it  is  not  completely  airtight,
since  there  is  the  possibility  of  establishing  microchannels
between  the  tracheal  mucous  and  the  cuff  when  it  is  dis-
tended,  which  increases  the  probability  of  microaspiration
of  the  accumulated  secretions  above  the  cuff  (subglottic
secretions)  to  the  lower  airways.25 In  addition,  pathogens
that  reach  the  ETT  cuff  are  able  to  colonize  the  interior
of  the  tube,  ensuring  access  to  the  distal  airways  with  the
aid  of  the  inspiratory  flow  from  the  MV,  establishing  posteri-
orly  the  lung  infection.24 Previous  surgeries  and  medication,
particularly  antibiotherapy,  may  also  predispose  the  patient
to  the  disease.5
Prevention  of  ventilator-associated  pneumonia
VAP  prevention  is  performed  through  pharmacological
and  non-pharmacological  measures  that  mainly  focus  on
modifiable  risk  factors.  With  this  review  our  intention  was
to  approach  the  most  consensual  preventive  measures
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Table  2  Risk  factors  of  VAP5,65,86--89
Risk  factors  of  VAP  related  with  the
host
Risk  factors  of  VAP  related
with  hospitalization  process
Risk  factors  of  VAP  related  with  drug
therapy
-  Advanced  age
-  Burns
-  Chronic  or  preexisting  pulmonary
disease  (tuberculosis,  chronic
obstructive  pulmonary  disease,b
bronchiolitis)
-  Cigarette  smoking
-  Coma
-  Gastric  colonization
- Immunosuppressive  diseasea
-  Impaired  consciousness
-  Male  gender
-  Malnutrition
-  Neurological/neuromuscular
disease
-  Organ  failure
- Oropharynx  colonization
- Post-operative  acute  respiratory
failure
- Post-surgical
-  Post-traumatic
-  Septicemia
-  Sinusitis
-  Traumac
-  Underlying  disease,  and  its
severity
-  Bronchoscopy
-  Emergency  intubationb
-  Endotracheal  intubation
-  Enteral  nutrition
- Frequent  changes  of  the  ventilator
circuit
- Gastric  aspirationb
-  High  frequency  of  antibiotic
resistance  in  the  hospital  unit  where
the patient  is  hospitalizeda
-  Hospitalization  ≥  5  daysa
-  Long-term  hospital  and  ICU  length
of stay.
- Long-term  intubation
- Mechanical  ventilation
- Multiple  central  venous  lines b
-  Nasogastric  tube
- Re-intubationc
-  Supine  body  position
- Thoracic  surgery
-  Tracheostomyc
-  Transportation  from  ICU  to  other
hospital  sites
-  Antacidsc
-  Antibiotic  therapy  in  the  previous
90 daysa
-  Excessive  sedation
-  H2-receptor  antagonists
- Imunosupressive  drugs
(corticosteroids)a
-  Intravenous  sedativesb
-  Neuromuscular  blockers
- Prior  exposure  to  antibiotics,
particularly  to  third-generation
cephalosporins
-  Proton  pump  inhibitors
- Red  blood  cells  transfusions
(immunomodulatory  effects)
- Stress  ulcer  prophylaxis
a Risk factor for multidrug-resistant pathogens.
b Specific risk factors of early-onset VAP.
c Specific risk factors of late-onset VAP.
A
B
C
D
E
F
Figure  1  Routes  of  colonization/infection  in  mechanically  ventilated  patients21 A  --  oral  and  pharyngeal  colonization;  B  --  gastric
colonization; C  --  infected  patients;  D  --  handling  of  respiratory  equipment;  E  --  use  of  respiratory  devices;  and  F  --  aerosols  from
contaminated  air.
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Table  3  Predominant  bacteria  in  ventilator-associated
pneumonia.10,85,90
Gram-positive  cocci
Methicillin-sensitive  Staphylococcus  aureus  (MSSA)
Methicillin-resistant  Staphylococcus  aureus  (MRSA)
Streptococcus  pneumoniae
Aerobic  Gram-negative  bacilli
Haemophilus  influenzae
Lactose  fermenting  Gram-negative  bacilli
Enterobacteriaceae
Enterobacter  spp.
Escherichia  coli
Klebsiella  pneumonia
Proteus  spp.
Serratia  spp.
Non-lactose  fermenting  Gram-negative  bacilli
Pseudomonas  aeruginosa
Acinetobacter  baumannii
that  are  described  in  guidelines  drawn  up  by  national  and
international  scientific  medical  societies  (Table  4 indicates
the  preventive  measures  that  each  guideline  recommends).
Noninvasive  mechanical  ventilation
The  first  step  in  the  prevention  of  VAP  is  the  patient
evaluation  in  order  to  determine  the  need  for  invasive
mechanical  ventilation.  MV  should  be  avoided  whenever
possible,5,21,25--30 since,  by  using  intubation,  the  risk  of  noso-
comial  pneumonia  is  increased  6--21  times.5
Although  noninvasive  MV  is  considered  a  feasible  alterna-
tive  to  invasive  MV  in  some  clinical  situations,  it  is  important
to  perceive  that  it  is  not  applicable  in  all  patients,  and
therefore  it  cannot  replace  MV  and  endotracheal  intuba-
tion  in  all  situations.  Noninvasive  MV  has  been  employed
with  favorable  clinical  results  in  cases  of:  exacerbation  of
chronic  obstructive  pulmonary  disease  (COPD),  cardiogenic
pulmonary  edema,  acute  hypoxemic  respiratory  failure  and
in  some  immunosuppressed  patients  with  pulmonary  infil-
trates  and  respiratory  failure.5,31 A  meta-analysis  of  12
studies,  in  which  the  target  population  had  COPD  as  the  pre-
vailing  disease,  concluded  that  noninvasive  positive  pressure
MV,  compared  with  invasive  positive  pressure  MV,  signifi-
cantly  decreased  mortality  and  incidence  of  VAP,  and  the
ICU  and  hospital  length  of  stay.32
The  use  of  noninvasive  MV  after  extubation  in  order  to
prevent  re-intubation  and  to  reduce  the  time  of  MV  (invasive
and  noninvasive)  has  been  investigated  and  the  results  are
now  promising.33 However,  more  studies  are  needed  in  order
to  get  a  better  understanding  of  its  role  in  VAP  prevention.
Until  now,  the  efficacy  of  this  measure  has  only  been  proven
in  patients  with  COPD.31
Weaning  from  invasive  mechanical  ventilation
The  weaning  from  invasive  MV  involves  a  close  monitoring
of  the  patient,  not  only  because  it  usually  occurs  in  an
intensive  care  environment,  but  also  because  the  monitor-
ing  of  signs  and  symptoms  is  essential  in  identification  of  a
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possible  failure  of  the  weaning  process:  increased  shortness
of  breath,  tachycardia,  diaphoresis,  oxygen  desaturation,
hypertension  and  increased  anxiety.34
Currently,  the  most  widely  used  weaning  method  is  the
spontaneous  breathing  trial  (SBT),  which  allows  the  obser-
vation  for  signs  of  respiratory  failure.  During  SBT  the  patient
breathes  spontaneously  through  the  ETT,  which  is  connected
to  a  T-piece.  The  T-piece  can  provide  a  source  of  humidified
oxygen  (without  mechanical  ventilator),  reduced  levels  of
continuous  positive  airway  pressure  and/or  pressure  support
ventilation  for  short  periods  of  time  (30  min--2  h).34,35
Since  it  is  difficult  to  predict  the  duration  of  MV,  the
current  guidelines  recommend  the  use  of  protocols  for
implementing  the  weaning  process  with  daily  assessments
of  the  patient,  in  order  to  assess  whether  there  are  the
necessary  conditions  to  begin  the  weaning  process.5,26--30
Ideally,  protocols  of  invasive  MV  weaning  include  wean-
ing  from  sedatives,  since  it  was  found  that  this  procedure
contributes  to  the  reduction  of  the  duration  of  MV  and
the  ICU  length  of  stay  and,  consequently,  to  reduce  the
risk  of  VAP.5,26--30,36 Indeed,  the  overuse  of  sedatives  is  not
beneficial  to  the  weaning  process,  as  it  can  inhibit  the
patient’s  breathing  capacity,  which  is  indispensable  to  the
discontinuation  of  MV.
Endotracheal  intubation
Guidelines  recommend  that  intubation  should  preferably  be
applied  with  orotracheal  and  orogastric  tubes,  instead  of
using  nasotracheal  or  nasogastric  tubes,  since  oral  intuba-
tion  is  associated  with  a  lower  incidence  of  VAP.5,25--29,37
Frequency  of  changes  of  the  ventilator  circuit
One  of  the  risk  factors  related  with  increased  hospital-
ization  is  the  frequent  change  of  the  ventilator  circuit.
Currently  it  is  consensual  that  one  circuit  only  should  be
used  in  each  patient,  and  that  it  should  only  be  changed
when  there  is  a  mechanical  damage  or  contamination
(blood,  vomit,  or  purulent  secretions).26,27,29,30,37,38 This
recommendation  is  based  on  the  evidence  that  frequent
changes  in  the  ventilator  circuit  do  not  contribute  to  a
decreased  incidence  of  VAP.39
Avoid  unnecessary  intra-hospital  transfers
Bercault  et  al.  found  that  an  episode  of  transport  from
the  ICU  to  another  place  in  the  hospital  increases  the  risk
of  development  of  VAP.40 It  is  thought  that  the  patient’s
positioning  in  supine  position,  and  the  frequent  handling
of  the  ventilator  tubing  during  the  transfers,  may  facili-
tate  the  aspiration  of  contaminated  secretions.29 Nowadays,
when  an  intra-hospital  transfer  is  needed  the  patient
should  be  in  an  inclined  position  and  enteral  nutrition
(EN)  should  be  suspended  4  h  before  the  transfer.28--30
Specific  prevention  of  microaspiration
a)  Elevation  of  the  head  of  the  bed
Elevation  of  the  head  of  the  bed  has  the  purpose  of
avoiding  positioning  the  patient  in  supine  position  --  a
position  whose  leaning  is  0◦ and  is  a  risk  factor  for
the  development  of  VAP,  in  order  to  prevent  gastroe-
sophageal  reflux  and  subsequent  aspiration  to  the  lower
airways.  In  fact,  elevation  of  the  head  of  the  bed  is
associated  with  a  reduced  risk  of  aspiration.27,29 A meta-
analysis  concluded  that  a  head  elevation  of  15--30◦ is
not  sufficient  to  prevent  the  development  of  VAP.41 At
present,  elevation  of  the  head  of  the  bed  between  30◦
and  45◦5,25--30 is  recommended,  but  there  are  already
some  studies  and  guidelines  that  would  only  consider
elevation  of  the  head  of  the  bed  at  45◦.37,41 The  use  of
the  horizontal--lateral  position  with  an  elevation  of  45◦
has  shown  promising  results,  because  compared  with  the
semi-recumbent  position,  it  has  had  a  lower  incidence  of
VAP  (4/10  versus  1/10).42 However,  this  measure  is  not
yet  included  in  guidelines  as  there  are  still  some  doubts
remain  to  be  cleared.
b) Modifications  in  endotracheal  tubes
Modifications  in  ETT  are  intended  to  prevent  mecha-
nisms  through  which  endotracheal  intubation  increases
the  risk  of  VAP:  1)  aspiration  of  secretions  into  the  lower
airways,  2)  mucosal  injury  and  decreased  mucociliary
clearance  of  secretions,  3)  microaspiration  of  secreti-
ons  around  the  inflated  cuff  and  4)  biofilm  formation  and
bacterial  colonization  in  the  ETT  lumen.43
In  order  to  replace  the  traditional  ETT,  which  have
polyvinylchloride  in  their  constitution,  antibacterial-
coated  ETT  have  been  developed;  the  most  studied
compound  is  silver,  which  has  bactericidal  activity  and
is  able  to  prevent  biofilm  formation.44 A  prospective
study  found  that  intubation  with  silver-coated  ETT  is
safe,  delays  the  ETT  colonization,  reduces  the  biofilm
formation  and  decreases  the  maximal  bacterial  burden
in  tracheal  secretions  for  7  days.45 Another  prospective
study  concluded  that  patients  intubated  with  silver-
coated  ETT  showed  lower  incidence  of  VAP,  delay  in
disease  onset  (with  higher  impact  in  the  first  10  days
of  intubation)46 and  decreased  mortality.47 Up  until  now,
no  study  has  reached  a  conclusion  about  the  influence  of
this  preventive  measure  in  the  duration  of  MV,  and  in  ICU
and  hospital  length  of  stay.  Therefore,  this  preventive
measure  is  still  not  consensual  among  the  scientific  com-
munity;  so  far  only  the  Spanish  guidelines  recommend
it.30 However,  it  is  worth  noting  that  a  cost-effectiveness
study  of  silver-coated  ETT  confirmed  that,  although
silver-coated  ETT  are  much  more  expensive  (60.22D )
than  conventional  tubes  (1.47D ),  they  reduced  the  hos-
pital  costs  from  between  7085.68D  and  12034.60D  per
prevented  case  of  VAP.48
The  improvement  of  the  ETT  cuff  has  also  been  tried
out,  both  in  terms  of  shape  as  well  as  its  inflation
characteristics,  in  order  to  prevent  microaspiration  of
subglottic  secretions.  The  studies  which  analyzed  ETT
with  polyurethane  cuffs  have  shown  good  results,  sug-
gesting  that  they  may  be  effective  in  the  prevention  of
microaspiration  of  secretions  to  the  lower  airways.49--52
However,  to  date,  none  of  the  studies  predicted  the
action  of  these  tubes  in  the  duration  of  MV  and  ICU  and
hospital  length  of  stay.
Another  recommendation  made  by  some  guidelines  is
related  to  the  cuff  pressure.  It  should  be  checked  daily,  at
regular  intervals,  and  maintained  between  20  and  30  cm
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H2O:  below  this  value  the  risk  of  pneumonia  increases,
and  above  it  tracheal  mucosal  injuries  can  occur.25,29
However,  the  British  guidelines  recommends  a  narrower
range  of  pressure  (>25  and  <30  cm  H2O)28 and  the  Amer-
ican  guidelines  only  recommend  a  minimum  value  of
20  cm  H2O.5,27
c)  Aspiration  of  subglottic  secretions
Currently,  aspiration  of  subglottic  secretions  is  recom-
mended  by  almost  all  guidelines,  since  studies  show  a
reduction  in  the  incidence  of  VAP  when  this  preventive
measure  is  used.5,25,27--30,37 The  meta-analysis  of  Dezfu-
lian  ital.  concluded  that  subglottic  secretion  drainage
reduced  the  incidence  of  VAP  by  almost  a  half,  and  that  in
patients  with  an  estimated  MV  time  of  more  than  72  h  this
measure  decreased,  on  average,  the  duration  of  MV  by  2
days,  the  ICU  length  of  stay  by  3  days,  and  delayed  the
onset  of  pneumonia  by  6.8  days.53 The  recommendations
concerning  the  use  of  aspiration  of  subglottic  secretions
differ  between  guidelines.  Canadian  guidelines  recom-
mend  it  in  patients  who  are  expected  to  require  MV  for
more  than  72  h,37 but  the  Spanish  have  reduced  the  time
to  48  h,30 and  the  British  recommend  the  implementation
of  this  measure  regardless  of  the  expected  MV  duration.28
Possibly  the  latter  approach  is  the  most  sensible,  because
it  is  very  difficult  to  predict  the  duration  of  MV.54
There  is  no  doubt  that  the  use  of  this  technique,
continuously  or  intermittently,  is  effective  in  the  pre-
vention  of  VAP,55--58 but  to  date  none  of  the  forms  of
aspiration  have  been  highlighted  as  the  best.  Currently,
both  are  implemented  in  order  to  prevent  and  reduce
microaspiration  and,  for  this  purpose,  specific  ETT  have
been  developed.  These  ETT  have  a  second  lumen  (aspi-
ration  lumen),  which  has  an  evacuation  orifice  in  the
edge  of  the  cuff  connected  to  a  suction  system,  allowing
continuous  or  intermittent  aspiration  of  the  subglottic
secretions.25,30,59
Control  of  the  colonization  of  the  oropharynx  and
the digestive  tract
A  major  aim  of  VAP  prevention  consists  in  reducing  the
colonization  of  the  oropharynx  and  the  digestive  tract,
since  they  represent  an  increased  risk  of  microaspiration  of
pathogens  to  the  lower  airways.21
a)  Oral  antiseptics
Patients  who  are  intubated  with  ETT  cannot  perform
their  daily  oral  hygiene,  which  carries  a  risk  of  biofilm
colonization  by  pathogenic  microorganisms.60 Oral  anti-
septics  have  been  used  in  order  to  reduce  and  prevent
oropharyngeal  colonization  by  bacterial  pathogens,  and
hence  this  is  a  viable  alternative  since  it  can  be  imple-
mented  by  health  care  providers.
The  use  of  oral  antiseptics  significantly  reduces  the
incidence  and  the  relative  risk  (RR  =  0.56)  of  VAP,  sug-
gesting  that  this  measure  is  efficient  in  its  prevention.61
Due  to  its  very  broad  spectrum  of  action,  which  covers
microorganisms  such  as  Pseudomonas  aeruginosa, Acine-
tobacter  spp.,  and  methicillin-resistant  Staphylococcus
aureus,62 some  of  the  most  common  pathogens  impli-
cated  in  VAP,  chlorhexidine  (CHX)  is  the  most  studied
antiseptic,  and  its  efficacy  in  the  prevention  of  VAP  has
been  proven.63,64 In  fact,  the  most  recent  guidelines  rec-
ommend  oral  decontamination  with  CHX  as  a  preventive
measure  of  VAP.25--27,30,37 However,  no  guidelines  recom-
mend  a  posology  for  this  preventive  measure.  Studies
used  concentrations  of  0.12%,  0.2%  and  2%  of  CHX  admin-
istered  2,  3  or  4  times  daily.62 A  more  recent  study
suggests  the  use  of  15  ml  of  an  oral  solution  of  0.12%  of
CHX  twice  a  day  until  24  h  after  extubation.65
The  Canadian  guideline  is  the  only  one  that,  besides
recommending  the  use  of  CHX  as  an  oral  antiseptic,  also
recommends  that  the  use  of  iodopovidone  should  be  con-
sidered  in  patients  with  severe  head  injury,  based  on  a
single  study  performed  in  this  patient  population.37
b)  Antibiotic  prophylaxis:  Selective  oropharyngeal  decon-
tamination  (SOD)  and  selective  digestive  decontamina-
tion  (SDD)
SOD  consists  of  enteral  administration  of  antimicrobial
agents,  while  in  SDD  the  parenteral  route  is  also  used.
These  decontaminations  are  selective  because  the  aim
is  to  prevent  the  oropharyngeal  and  gastric  colonization
by  aerobic  Gram-negative  bacilli,  S.  aureus  and  fungi
species  like  Candida,  without  affecting  the  commensal
flora.65 Antimicrobial  regimens  studied  do  not  vary  very
much.  They  consist  essentially  in  the  administration  four
times  a  day  of  antibiotics  that  act  only  in  the  gastroin-
testinal  tract,  i.e.  which  are  not  absorbed  (e.g.,  colistin,
polymyxin  E,  tobramycin  and/or  amphotericin  B),  and
antibiotics  administered  intravenously  (e.g.  cefotaxime
or  ciprofloxacin)  in  the  case  of  SDD.54,62
de  Smet  et  al.  have  conducted  the  largest  study
concerning  SOD  and  SDD  to  date,  they  confirmed  a
2.9%  decrease  in  the  mortality  rate  with  SOD,  and  a
3.5%  decrease  with  SDD.  Both  decontamination  proce-
dures  reduced  the  duration  of  MV,  ICU  and  hospital
length  of  stay,  daily  doses  of  antimicrobials  and  the
incidence  of  ICU-acquired  bacteremia  caused  by  S.
aureus,  P.  aeruginosa  and  Enterobacteriaceae. Moreover,
isolation  of  Gram-negative  bacteria  decreased  consider-
ably  in  patients  who  were  treated  with  SOD  and  SDD.
Authors  defend  the  administration  of  DSO  because  it
does  not  include  widespread  systemic  prophylaxis  with
cephalosporins,  and  so  avoids  the  increase  of  antibiotic
resistance  in  ICU.66 However,  this  study  has  a  characteris-
tic  that  has  prevented  the  generalized  recommendation
of  SOD  and  SDD:  antibiotic  resistance  recorded  in  the
studied  ICU  (Holland)  is  considered  low  (<5%)  when  com-
pared  to  the  rates  of  antibiotic  resistance  in  other
countries  such  as  the  USA.54,65 Studies  in  different
locations,  with  different  rates  of  antibiotic  resistance,
are  needed  in  order  to  obtain  a  better  and  more
widespread  perception  of  the  long-term  effect  of  these
measures.
A  later  study,  carried  out  in  the  same  ICU,  evaluated
the  impact  of  SOD  and  SDD  on  antibiotic  resistance  in
Gram-negative  bacteria,  concluding  that  although  SOD
and  SDD  reduced  mortality,  both  measures  were  asso-
ciated  with  a  gradual  increase  in  antibiotic  resistance,
primarily  to  ceftazidime.67 Thus,  American  guidelines
and  other  more  recent  ones  do  not  recommend  routine
use  of  prophylactic  antibiotics  and  SDD,  due  to  concerns
about  the  rising  problem  of  antibiotic  resistance.5,30,37
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c)  Probiotics
Probiotics  are  viable  microorganisms  present  in  suffi-
cient  number  so  that  they  can  have  a  beneficial  effect  on
the  health  of  the  host,  which  is  achieved  by  colonization
and  changes  of  the  microflora  in  a  compartment  of  the
host  (e.g.  oral  cavity,  gut),  where  they  remain  temporar-
ily,  favoring  the  growth  of  bacterial  species  beneficial  to
the  organism,  and  decreasing  the  presence  of  potential
pathogens.68,69
A  meta-analysis  including  five  studies  that  analyzed
the  effect  of  probiotics  in  ventilated  patients,  concluded
that  its  implementation  reduced  the  incidence  of  VAP,
ICU  length  of  stay  and  colonization  of  the  respiratory
tract  by  P.  aeruginosa; however,  no  differences  were
observed  in  mortality  rates  and  MV  duration.70 Two  other
studies  that  were  not  included  in  the  mentioned  analy-
sis  also  proved  the  efficacy  (reduction  of  VAP  incidence
and  antibiotics  use)  and  safety  of  probiotics  adminis-
tration  in  the  prevention  of  VAP.69,71 It  is  a  fact  that
probiotics  administration  has  been  shown  to  be  promising
in  preventing  VAP,  possibly  representing  an  alternative  to
antibiotic  prophylaxis,  due  to  the  increasing  problem  of
resistance.  However,  to  date,  no  guidelines  recommend
their  use.  More  studies  are  needed,  with  more  represen-
tative  patient  populations,  in  order  to  extrapolate  the
results.
Disinfection  and  antisepsis
Besides  all  specific  measures  to  prevent  VAP,  guidelines  also
recommend  one  of  the  most  basic  and  common  preventive
measures  of  nosocomial  infections:  hygiene  and  disinfec-
tion  of  the  hospital  environment,  healthcare  professionals
and  medical  devices.5,26--30 Regarding  the  latter,  disinfection
of  the  respiratory  equipment,  removal  of  the  condensate
with  the  ventilator  circuit  closed  during  the  procedure,  and
use  of  sterile  water  when  rinsing  the  reusable  devices  are
recommended.
Adherence  to  hand  hygiene  programs  is  considered  one
of  the  most  important  preventive  measures  of  healthcare-
associated  infections,72 and  also  has  the  advantage  of  being
cheap.  The  CDC  Guideline  for  Hand  Hygiene  in  Health-
Care  Settings  analyzed  data  from  observational  studies
concluding  that  the  percentage  of  health  professionals  who
implement  the  recommended  procedures  for  hand  hygiene  is
highly  variable,  with  an  overall  average  of  40%.73 In  order  to
reduce  poor  adherence,  training  of  health  professionals  and
assessment  of  their  performance,  distribution  of  information
leaflets  and  lectures  are  suggested.74
Enteral nutrition
EN  is  considered  a  risk  factor  for  the  development  of  pneu-
monia,  because  it  increases  the  risk  of  aspiration  of  the
gastric  content  to  the  lower  airways.5,75 However,  in  ven-
tilated  patients  who  have  a  critical  condition,  its  use  is
unavoidable  and  necessary,  because  it  avoids  the  develop-
ment  of  a  catabolic  state28 and  decreases  the  incidence  of
infectious  complications  and  hospitalization  costs.76 Addi-
tionally,  ventilation  time  is  greater  when  patients  are  fed
by  parenteral  route.77 A  large-scale  study  determined  the
impact  of  early  (administered  within  the  first  48  h  of  MV)
versus  late  EN  on  ICU  and  hospital  mortality  of  mechanically
ventilated  patients.  Authors  concluded  that  early  adminis-
tration  of  EN  was  associated  with  lower  rates  of  ICU  and
hospital  mortality,  especially  in  those  patients  with  a  worse
health  condition;  however  it  increased  the  risk  of  devel-
opment  of  VAP.  Since  the  increased  risk  of  VAP  was  not
associated  with  an  increased  mortality,  authors  recommend
early  administration  of  EN,  mainly  in  patients  who  are  at
high  risk  of  death.78
The  UK  guidelines  recommend  that  the  rate  and  vol-
ume  of  EN  should  be  adjusted  to  avoid  gastric  distension
in  order  to  prevent  aspiration  of  gastric  content  to  the
lower  airways.28 As  the  semi-recumbent  position  (30--45◦)
has  been  associated  with  the  prevention  of  aspiration  of
gastric  content,  guidelines  consider  it  essential  when  the
patient  is  fed  by  EN,  which  should  be  administered  as  soon
as  possible.5,25,26,29,30
Education  and  training  for  health  professionals
Some  guidelines  emphasize  the  importance  of  VAP  educa-
tion  and  training  programs  for  health  professionals  who
are  directly  involved  in  providing  health  care  to  patients
under  MV,5,26--30 since  it  is  associated  with  proven  efficacy
in  reducing  the  incidence  of  VAP  by  50%.79 A  questionnaire
carried  out  with  1200  USA  nurses  revealed  that  only  82%
adhere  to  hand-washing  practices,  77%  use  gloves,  52%
raise  the  head  of  the  bed  to  30--45◦ during  the  entire  day
and  36%  aspirate  the  subglotic  secretions;  it  also  revealed
that  nurses  who  used  a  protocol  of  oral  hygiene  were
associated  with  a  greater  knowledge  of  the  disease  and  a
higher  compliance  with  good  service  practices  to  reduce
the  risk  of  VAP.80 There  are  reasons  for  non-compliance  with
guidelines  by  health  professionals,  such  as  disagreement
with  the  results  of  the  studies,  patient  discomfort,  fear  of
adverse  effects,  lack  of  resources  and  the  associated  costs
with  preventive  measures.29
Bundles
A  bundle  consists  of  a  small  set  of  preventive  measures
with  proven  efficacy,  which  ensures  more  efficient  preven-
tion  of  the  disease,  compared  to  the  sum  of  their  individual
implementation.25,54,81
Most  of  the  hospital  teams  that  have  evaluated  preven-
tive  measures  for  VAP,  have  implemented  the  bundle  devel-
oped  by  the  Institute  for  Healthcare  Improvement  which  is
composed  of:  elevation  of  the  head  of  the  bed  between
30◦ and  45◦,  daily  sedation  interruption  and  assessment  of
readiness  to  extubate,  daily  oral  care  with  CHX,  peptic  ulcer
disease  prophylaxis  and  deep  vein  thrombosis  prophylaxis.82
A  3-year  study  analyzed  the  impact  of  a  slight  modifica-
tion  to  this  bundle  (without  daily  oral  care  with  CHX),  veri-
fying  the  decrease  of  hospitalization  charges  and  the  rate  of
VAP.83 A  literature  review  that  includes  several  studies  that
have  implemented  bundles  to  prevent  VAP  concluded  that
the  bundles  decrease  the  incidence  of  VAP,  duration  of  MV,
ICU  length  of  stay,  mortality  and  associated  costs.84
There  is  no  complete  concordance  between  the  pre-
ventive  measures  included  in  the  studied  bundles  and
the  recommendations  of  the  most  recent  guidelines.  In
fact,  deep  vein  thrombosis  prophylaxis  is  not  indicated
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in  any  guidelines  as  a  preventive  measure  of  VAP  and,
although  peptic  ulcer  disease  prophylaxis  is  present  in  some
guidelines,  it  is  not  recommended  on  a  routine  basis.5,28
Therefore,  studies  are  needed  to  assess  bundles  that  include
measures  recommended  by  the  most  recent  guidelines,
in  order  to  evaluate  if  they  have  a  synergistic  effect  on
patient’s  clinical  outcomes  and  in  the  decrease  of  VAP  inci-
dence,  when  implemented  together.
Conclusion
Over  the  last  few  years  there  has  been  a  noticeable  effort
to  develop  and  improve  preventive  measures  to  reduce  the
incidence  of  VAP.  It  is  crucial  that  this  effort  continues
because,  although  the  strategies  developed  in  recent  years
are  promising,  VAP  remains  a  nosocomial  problem  which  is
difficult  to  control,  with  high  rates  of  mortality,  morbidity
and  hospital  costs.
The  preventive  strategy  of  VAP  focuses  on  modifiable
risk  factors,  with  several  pharmacological  and  non-
pharmacological  measures  available,  which  aim  to  reduce
the  risk  associated  with  endotracheal  intubation  and  pre-
vent  the  microaspiration  of  pathogens  to  the  lower  airways.
Preventive  measures  include  avoidance  of  endotracheal
intubation  and  use  of  noninvasive  MV  whenever  possible,
preference  of  orotracheal  and  orogastric  tubes,  weaning  of
ventilation  combined  with  weaning  of  sedatives,  use  of  a
single  ventilator  circuit  per  patient,  use  of  antibacterial-
coated  ETT  preferably  with  a  polyurethane  cuff,  aspiration
of  subglottic  secretions,  patient  positioning,  avoidance  of
unnecessary  intra-hospital  transfers,  preference  for  enteral
nutrition,  use  of  oral  antiseptics,  good  hygiene  practices  by
health  professionals,  and  disinfection  of  hospital  settings
and  medical  devices.
Administration  of  probiotics  has  shown  promising  results,
although,  to  date,  no  guidelines  recommend  its  use.  The
most  promising  preventive  measures  in  the  near  future  are
the  development  of  new  ETT  and  bundles.  However,  devel-
opment  of  a  bundle  that  contains  the  current  recommended
preventive  measures,  in  guidelines  issued  by  scientific  medi-
cal  societies,  is  still  lacking.
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